The global medical affairs outsourcing market accounted for USD 2.00 billion in 2023 and is expected to reach at USD 8.20 billion by 2034 with a CAGR of 13.68% during the forecast period 2024-2034. The market will grow owing to the increasing complexity of the regulatory landscape, the focus on core competencies, the globalization of clinical trials, the rising demand for real-world evidence (RWE), the expansion of product portfolios and market presence, technological and data analytics advancements, and the shift toward value-based healthcare.
There is an increasing emphasis on producing real-world evidence to supplement standard clinical trial data. Medical affairs outsourcing providers contribute significantly to the generation, analysis, and dissemination of RWE through activities like as observational studies, post-marketing surveillance, and health economic outcomes research. This information is useful for guiding healthcare decisions, facilitating market access initiatives, and showing product value. For instance, in January 2023, ICON announced an expansion of its strategic alliance with IBM Watson Health to improve clinical trial monitoring and speed up patient enrollment.
By service type, the medical writing and publishing segment accounted for the highest revenue-grossing segment in the global medical affairs outsourcing market in 2023 owing to the high demand for regulatory documentation, scientific publications, and promotional materials required for drug development, regulatory submissions, and market access strategies. For instance, Syneos Health announced in December 2023 that it acquired Illingworth Research Group, a renowned provider of clinical research services. This acquisition broadens Syneos Health's expertise in patient-centered trial design and implementation. Additionally, the medical science liaison (MSL) services segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing importance of scientific engagement with key opinion leaders (KOLs), healthcare professionals, and academic institutions to disseminate medical information, support clinical trial recruitment, and facilitate collaborative research partnerships.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global medical affairs outsourcing market in 2023 owing to the growing prevalence of cancer, rapid advancements in oncology treatments, and the complexity of regulatory and market access requirements specific to oncology products. For instance, in November 2023, IQVIA announced the formation of IQVIA MedTech, a new business unit dedicated to providing medical device and diagnostics firms with end-to-end solutions, including medical affairs assistance. Additionally, the immuno-oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of immuno-oncology research and development, driven by the promising results of immunotherapy approaches in cancer treatment.
By end-user, the pharmaceutical and biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global medical affairs outsourcing market in 2023 owing to the increasing outsourcing of medical affairs functions by pharmaceutical and biopharmaceutical companies to focus on core activities like drug development and commercialization, as well as to efficiently manage costs and leverage specialized expertise offered by outsourcing partners. For instance, in February 2023, Parexel announced an agreement with TriNetX, a worldwide health research network, to improve real-world evidence gathering and accelerate clinical trial design and recruiting. Additionally, the contract research organizations (CROs) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for outsourcing clinical trial management and regulatory support services, as pharmaceutical and biopharmaceutical companies seek to streamline operations, reduce costs, and accelerate drug development timelines.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established pharmaceutical and biotechnology industry, extensive outsourcing of medical affairs functions, favourable regulatory environment, robust healthcare infrastructure, and high healthcare expenditure. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of outsourcing services by pharmaceutical companies, expanding clinical trial activities, rising investments in healthcare infrastructure, and the growing prevalence of chronic diseases. For instance, in January 2024, PRA Health Sciences announced the acquisition of CareLex, a supplier of regulatory affairs and quality compliance consulting services, to expand its regulatory expertise and global presence.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
There is an increasing emphasis on producing real-world evidence to supplement standard clinical trial data. Medical affairs outsourcing providers contribute significantly to the generation, analysis, and dissemination of RWE through activities like as observational studies, post-marketing surveillance, and health economic outcomes research. This information is useful for guiding healthcare decisions, facilitating market access initiatives, and showing product value. For instance, in January 2023, ICON announced an expansion of its strategic alliance with IBM Watson Health to improve clinical trial monitoring and speed up patient enrollment.
By service type, the medical writing and publishing segment accounted for the highest revenue-grossing segment in the global medical affairs outsourcing market in 2023 owing to the high demand for regulatory documentation, scientific publications, and promotional materials required for drug development, regulatory submissions, and market access strategies. For instance, Syneos Health announced in December 2023 that it acquired Illingworth Research Group, a renowned provider of clinical research services. This acquisition broadens Syneos Health's expertise in patient-centered trial design and implementation. Additionally, the medical science liaison (MSL) services segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing importance of scientific engagement with key opinion leaders (KOLs), healthcare professionals, and academic institutions to disseminate medical information, support clinical trial recruitment, and facilitate collaborative research partnerships.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global medical affairs outsourcing market in 2023 owing to the growing prevalence of cancer, rapid advancements in oncology treatments, and the complexity of regulatory and market access requirements specific to oncology products. For instance, in November 2023, IQVIA announced the formation of IQVIA MedTech, a new business unit dedicated to providing medical device and diagnostics firms with end-to-end solutions, including medical affairs assistance. Additionally, the immuno-oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of immuno-oncology research and development, driven by the promising results of immunotherapy approaches in cancer treatment.
By end-user, the pharmaceutical and biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global medical affairs outsourcing market in 2023 owing to the increasing outsourcing of medical affairs functions by pharmaceutical and biopharmaceutical companies to focus on core activities like drug development and commercialization, as well as to efficiently manage costs and leverage specialized expertise offered by outsourcing partners. For instance, in February 2023, Parexel announced an agreement with TriNetX, a worldwide health research network, to improve real-world evidence gathering and accelerate clinical trial design and recruiting. Additionally, the contract research organizations (CROs) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for outsourcing clinical trial management and regulatory support services, as pharmaceutical and biopharmaceutical companies seek to streamline operations, reduce costs, and accelerate drug development timelines.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established pharmaceutical and biotechnology industry, extensive outsourcing of medical affairs functions, favourable regulatory environment, robust healthcare infrastructure, and high healthcare expenditure. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of outsourcing services by pharmaceutical companies, expanding clinical trial activities, rising investments in healthcare infrastructure, and the growing prevalence of chronic diseases. For instance, in January 2024, PRA Health Sciences announced the acquisition of CareLex, a supplier of regulatory affairs and quality compliance consulting services, to expand its regulatory expertise and global presence.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Service Type, Therapeutic Area, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Medical Affairs Outsourcing Market Report 2023 - 2034
Medical Affairs Outsourcing Market Analysis & Forecast by Service Type 2023 - 2034 (Revenue USD Bn)
- Medical writing and publishing
- Medical science liaison (MSL) services
- Medical information support
- Medical education and training
- Medical communications
- Regulatory affairs support
- Pharmacovigilance and drug safety services
Medical Affairs Outsourcing Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Oncology
- Cardiovascular diseases
- Neurology
- Infectious diseases
- Immunology
- Endocrinology
- Respiratory diseases
- Others
Medical Affairs Outsourcing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical companies
- Biotechnology companies
- Contract research organizations (CROs)
- Medical device companies
- Academic and research institutes
Medical Affairs Outsourcing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Medical Affairs Outsourcing Market: Service Type Estimates & Trend Analysis
8. Medical Affairs Outsourcing Market: Therapeutic Area Estimates & Trend Analysis
9. Medical Affairs Outsourcing Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Medical Affairs Outsourcing Market
12. Europe Global Medical Affairs Outsourcing Market
13. Asia Pacific Global Medical Affairs Outsourcing Market
14. Latin America Global Medical Affairs Outsourcing Market
15. MEA Global Medical Affairs Outsourcing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- ICON plc
- Syneos Health
- IQVIA
- Parexel International Corporation
- PRA Health Sciences
- Charles River Laboratories
- Covance Inc.
- Medpace Holdings Inc.
- Wuxi AppTec
- Kinapse (a Syneos Health company)
- Premier Research
- PPD Inc.
- ProPharma Group
- SGS SA
- Criterium Inc.
